$XNCR

Montgomery Alan Bruce sold $62K of XNCR

Montgomery Alan Bruce sold 5,064 shares of Xencor Inc (XNCR) at $12.31 on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Montgomery Alan Bruce
Published Jun 17, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$XNCR
Neutral
high confidence
Mentioned
$XNCR
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$XNCRNeutralLow
01

Why it matters

This disclosure updates the insider transaction record but does not introduce new company fundamentals (no earnings, guidance, trial, or deal information).

02

Market read

A director’s 10b5-1 sale is typically low-signal; any trading impact is usually limited unless corroborated by additional new disclosures.

03

What to watch

The article provides only the sale details; it does not state whether other insiders bought/sold around the same window or whether the company had concurrent news.

Relevance 2/10Novelty 3/10Timing: Filed 2026-06-17; sale executed 2026-06-15.

Background

The article is an SEC Form 4 disclosure of an insider transaction for Xencor, Inc.

Company-level read

Ticker impact

$XNCRNeutralHigh confidence
Context

Xencor director Montgomery Alan Bruce sold 5,064 shares in an open-market transaction on 2026-06-15 under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction likely fades quickly unless paired with other new fundamentals.

Evidence & confidence

The filing is a Form 4 insider sale with a pre-arranged 10b5-1 plan and no accompanying company-specific operational or financial catalyst in the text.

Market effects

No sector read-through; this is a single-company insider transaction with no new product/clinical/regulatory information.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with perceived valuation risk; traders may watch for follow-on sales or changes in buying behavior.

Key entities

  • Xencor, Inc.

    Issuer of the Form 4 insider transaction; director sold shares under a 10b5-1 plan.

  • Montgomery Alan Bruce

    Director who executed the open-market sale of 5,064 shares on 2026-06-15.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$XNCRHighAI 8/10

Truist raises Xencor stock price target on kidney cancer drug data

Truist Securities raised its price target for Xencor (XNCR) to $40 from $29, citing positive clinical data for XmAb819 in kidney cancer. The stock has gained 17% in a week. Truist increased peak sales estimates to $1.1B and success probability to 35%. XNCR's market cap is $2.18B, with a 91% YTD return. Other analysts also upgraded price targets based on ESMO conference data.